GSK (LON:GSK) Stock Rating Reaffirmed by Shore Capital

Posted by on May 6th, 2023

GSK (LON:GSK – Get Rating)‘s stock had its “buy” rating reaffirmed by research analysts at Shore Capital in a research report issued to clients and investors on Thursday, MarketBeat.com reports.

A number of other brokerages have also issued reports on GSK. JPMorgan Chase & Co. restated an “underweight” rating and set a GBX 1,400 ($17.49) target price on shares of GSK in a research report on Thursday, April 27th. Berenberg Bank reiterated a “buy” rating and set a GBX 1,730 ($21.61) price target on shares of GSK in a research report on Wednesday, April 19th. Barclays reiterated an “equal weight” rating and set a GBX 1,450 ($18.12) price target on shares of GSK in a research report on Thursday, April 27th. UBS Group set a GBX 1,245 ($15.55) price target on shares of GSK in a research report on Wednesday, February 1st. Finally, Credit Suisse Group reiterated a “neutral” rating and set a GBX 1,510 ($18.87) price target on shares of GSK in a research report on Thursday, February 2nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of GBX 1,573.33 ($19.66).

GSK Stock Performance

Shares of LON:GSK opened at GBX 1,462.40 ($18.27) on Thursday. The company’s 50 day moving average price is GBX 1,449.34 and its two-hundred day moving average price is GBX 1,433.84. GSK has a 12-month low of GBX 1,280.92 ($16.00) and a 12-month high of GBX 2,746.59 ($34.32). The firm has a market cap of £59.23 billion, a PE ratio of 1,366.73, a PEG ratio of 2.04 and a beta of 0.28. The company has a quick ratio of 0.73, a current ratio of 0.95 and a debt-to-equity ratio of 184.80.

Insider Buying and Selling at GSK

In other news, insider Emma Walmsley sold 28,576 shares of the firm’s stock in a transaction on Tuesday, February 14th. The shares were sold at an average price of GBX 1,487 ($18.58), for a total transaction of £424,925.12 ($530,890.95). In other news, insider Emma Walmsley sold 28,576 shares of the firm’s stock in a transaction on Tuesday, February 14th. The shares were sold at an average price of GBX 1,487 ($18.58), for a total transaction of £424,925.12 ($530,890.95). Also, insider Iain Mackay bought 200 shares of the stock in a transaction that occurred on Tuesday, April 18th. The shares were purchased at an average cost of GBX 1,493 ($18.65) per share, with a total value of £2,986 ($3,730.63). Insiders have purchased 2,308 shares of company stock worth $3,248,612 over the last quarter. Corporate insiders own 1.75% of the company’s stock.

About GSK

(Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Further Reading

Analyst Recommendations for GSK (LON:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.